A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

Fowler et al., NCT04330690, CATCO, NCT04330690, May 2024
Estimated 580 patient LSALT peptide late treatment RCT with results not reported over 1.5 years after estimated completion.
Study covers LSALT peptide and artemisinin.
Fowler et al., 18 May 2024, Randomized Controlled Trial, Canada, trial NCT04330690 (history) (CATCO). Contact: rob.fowler@sunnybrook.ca, CATCO@sunnybrook.ca, atrembla@ucalgary.ca, cjdumonc@ucalgary.ca, conar@ualberta.ca, Matt.Munan@covenanthealth.ca, wendy.sligl@ahs.ca, Kimberly.Robertson2@albertahealthservices.ca, Caitlyn.Marek@interiorhealth.ca, Mai.Hayashi@interiorhealth.ca, james.douglas@vch.ca, Valla.sahraei@vch.ca, jennifer.grant@vch.ca, Gabriel.Loh@vch.ca, allimah@mail.ubc.ca, laura.oliveira@ubc.ca, npress@cfenet.ubc.ca, llove@cheos.ubc.ca, daniel.ovakim@viha.ca, fiona.auld@viha.ca, yoav.keynan@umanitoba.ca, nchoi@hsc.mb.ca, Peter.Daley@easternhealth.ca, laura.genge@easternhealth.ca, lisa.barrett@nshealth.ca, barbara.goodall@nshealth.ca, Alexandra.Binnie@williamoslerhs.ca, sergio.borgia@williamoslerhs.ca, thomas.havey@williamoslerhs.ca, Erick.duan@medportal.ca, clarkef@mcmaster.ca, Michael.Silverman@sjhc.london.on.ca, SeemaNair.Parvathy@sjhc.london.on.ca, efera@msh.on.ca, nshah@msh.on.ca, Christopher.Graham@thp.ca, Mobina.Khurram@thp.ca, senglish@ohri.ca, iwatpool@ohri.ca, nicolaschagnon@montfort.on.ca, christinencompas@montfort.on.ca, rporteous@ohri.ca, jennifer.tsang@mail.utoronto.ca, Lisa.patterson@niagarahealth.on.ca, sjohn@shn.ca, crobb@shn.ca, gambleg@me.com, moonl@tbh.net, christopher.kandel@one-mail.on.ca, jeff.powis@tehn.ca, Asgar.Rishu@sunnybrook.ca, Darrell.tan@gmail.com, Attia.Qamar@unityhealth.to, michael.fralick@sinaihealth.ca, bryan.Coburn@uhn.ca, kevin.schwartz@unityhealth.to, kanthi.kavikondala@unityhealth.to, madeleine.durand.chum@ssss.gouv.qc.ca, stephanie.matte.chum@ssss.gouv.qc.ca, matthew.cheng@mcgill.ca, sondramandy.sinanan@muhc.mcgill.ca, alexis.turgeon@crchudequebec.ulaval.ca, David.Bellemare@crchudequebec.ulaval.ca, francois.lellouche@criucpq.ulaval.ca, patricia.lizotte@criucpq.ulaval.ca, francois.lamontagne@usherbrooke.ca, marie-pier.bouchard.ciussse-chus@ssss.gouv.qc.ca.
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit